Change search
ReferencesLink to record
Permanent link

Direct link
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study
KTH, School of Architecture and the Built Environment (ABE), Transport and Economics, Safety Research.ORCID iD: 0000-0001-7606-8771
Show others and affiliations
2007 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 21, no 4, 627-632 p.Article in journal (Refereed) Published
Abstract [en]

This randomized study assessed if intravenous iron improves hemoglobin (Hb) response and permits decreased epoetin dose in anemic (Hb 9 - 11 g/dl), transfusion-independent patients with stainable iron in the bone marrow and lymphoproliferative malignancies not receiving chemotherapy. Patients (n = 67) were randomized to subcutaneous epoetin beta 30 000 IU once weekly for 16 weeks with or without concomitant intravenous iron supplementation. There was a significantly (P < 0.05) greater increase in mean Hb from week 8 onwards in the iron group and the percentage of patients with Hb increase >= 2 g/dl was significantly higher in the iron group (93%) than in the no-iron group (53%) (per-protocol population; P < 0.001). Higher serum ferritin and transferrin saturation in the iron group indicated that iron availability accounted for the Hb response difference. The mean weekly patient epoetin dose was significantly lower after 13 weeks of therapy (P < 0.029) and after 15 weeks approximately 10 000 IU (425%) lower in the iron group, as was the total epoetin dose (P = 0.051). In conclusion, the Hb increase and response rate were significantly greater with the addition of intravenous iron to epoetin treatment in iron-replete patients and a lower dose of epoetin was required.

Place, publisher, year, edition, pages
2007. Vol. 21, no 4, 627-632 p.
Keyword [en]
anemia, cancer, erythropoietin, intravenous iron, lymphoproliferative malignancies
National Category
Medical and Health Sciences
URN: urn:nbn:se:kth:diva-9954DOI: 10.1038/sj.leu.2404562ISI: 000245117600007ScopusID: 2-s2.0-33947405774OAI: diva2:173476
QC 20100826Available from: 2009-02-20 Created: 2009-02-16 Last updated: 2010-09-01Bibliographically approved
In thesis
1. Risk, Risk Analysis and Decision-making with Reference to Biostatistics and the Field of Medicine
Open this publication in new window or tab >>Risk, Risk Analysis and Decision-making with Reference to Biostatistics and the Field of Medicine
2010 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Risk, risk analysis and decision-making are essential aspects of health care andmedicine, for patients as well as for physicians and for society as a whole, andthe concept of risk and risk analysis in decision-making has a long history. Theword risk has many different interpretations and has no commonly accepteddefinition. In this thesis, we shall let risk stand for the combination of randomor uncertain events with negative consequences for human health, life and/orwelfare and/or the environment together with some measures of the likelihoodof such events. We believe this is the dominant concept and understanding ofrisk, the risk being the likelihood or probability of an event followed by somenegative consequences or activities of that event.

In this doctoral thesis, we focus on biostatistics, risks and risk analysis in thefield of medicine, a science which has been using methods from the area of riskanalysis for a long time. The seven papers (paper I - paper VII) presented inthis thesis, together with a general introduction to risk, risk analysis anddecision-making, will be used to illustrate and discuss risk analysis as a tool fordecision-making in the field of medicine. From my point a view, risk analysisin the field of medicine aims to reduce pain, raise the quality of life, reduce therisk of adverse events, compare cost efficiency between different treatmentregimes and prolong a healthy life. Based on results presented in the thesis, weconclude that biostatistics, risks and risk analysis used in the field of medicineare valuable methods for evaluation of hypotheses within the health care areaand a good basis for decision-making.

Place, publisher, year, edition, pages
Stockholm: KTH, 2010. 51 p.
Trita-TEC-PHD, ISSN 1653-4468 ; 10:004
risk analysis, risk, consequence, system, biostatistics, decision, decision-making, health care, medicine
National Category
Medical Laboratory and Measurements Technologies
urn:nbn:se:kth:diva-24304 (URN)978-91-8559-62-8 (ISBN)
Public defence
2010-09-15, F3, Lindstedtsvägen 26, KTH, Stockholm, 10:15 (English)
QC20100901Available from: 2010-09-01 Created: 2010-09-01 Last updated: 2010-09-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Näsman, Per
By organisation
Safety Research
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 54 hits
ReferencesLink to record
Permanent link

Direct link